M23-385: what clinicians are saying
ABBV-706; ABBV-706 plus budigalimab; ABBV-706 plus platinum-based chemotherapy in advanced solid tumors · NCT05599984 ↗ · Phase 1 · AbbVie
A medical oncologist supports further study of M23-385 because of responses despite platinum resistance, but their pulmonary reassurance applies only to the budigalimab combination. Fatal treatment-related pneumonitis was reported with monotherapy; these accounts do not demonstrate disagreement within the same cohort. Another medical oncologist qualifies their favorable reading by stressing small cohorts. Survival observations remain preliminary, and neither budigalimab’s added benefit nor benefit after tarlatamab is established.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 69 verified statements
This edition $750, with MCP access for your AI agent. Get this report
10 findings, and what sits behind each
01. ABBV-706: most clinicians highlight safety with budigalimab; one relays deaths
3 of the report's 11 cited clinicians · 8 statements from 3 speakers in 4 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 4.
Draws on: Primary endpoint: Percentage of Participants With Adverse Events (AE), The comparison, Safety and tolerability, Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors, Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706, Design and conduct, Primary endpoint: Progression-Free Survival (PFS), Primary endpoint: Overall survival (OS).
02. ABBV-706 alone: most speakers highlight ORR, but some clinicians flag small numbers
5 of the report's 11 cited clinicians · 14 statements from 6 speakers in 9 sources, 1 of them a podcast or video · 15 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors, Primary endpoint: Overall survival (OS), Population and setting, Design and conduct, Primary endpoint: Progression-Free Survival (PFS), The comparison, Primary endpoint: Percentage of Participants With Adverse Events (AE), Primary endpoint: Duration of response (DOR) for Participants with Confirmed CR/PR, Safety and tolerability.
03. ABBV-706 monotherapy dose: how a clinician frames the efficacy–safety balance
2 of the report's 11 cited clinicians · 10 statements from 2 speakers in 5 sources, 1 of them a podcast or video · 9 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706, The comparison, Safety and tolerability, Primary endpoint: Percentage of Participants With Adverse Events (AE), Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors, Primary endpoint: Overall survival (OS), Design and conduct.
04. ABBV-706 + budigalimab: what speakers say
3 of the report's 11 cited clinicians · 7 statements from 3 speakers in 4 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors, The comparison, Primary endpoint: Percentage of Participants With Adverse Events (AE), Safety and tolerability, Primary endpoint: Progression-Free Survival (PFS), Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706, Primary endpoint: Overall survival (OS), Design and conduct.
05. Subtype and prior Cisplatin: what a speaker asks; a clinician notes a ctDNA link
2 of the report's 11 cited clinicians · 6 statements from 3 speakers in 5 sources · 5 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Progression-Free Survival (PFS), Primary endpoint: Overall survival (OS), Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors.
06. Other NENs: what clinicians highlight in early ABBV-706 activity and unmet need
3 of the report's 11 cited clinicians · 7 statements from 3 speakers in 4 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 3.
Draws on: Population and setting, Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors, Design and conduct.
07. ABBV-706: a clinician seeks larger trials; one sees scope if tarlatamab fails
2 of the report's 11 cited clinicians · 5 statements from 2 speakers in 3 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 2.
Draws on: Population and setting.
08. SEZ6: why most speakers welcome development; some clinicians welcome the phase 1 paper
5 of the report's 11 cited clinicians · 9 statements from 6 speakers in 7 sources, 1 of them a podcast or video · 8 passages
Limitations recorded: 3.
Draws on: Population and setting.
09. ABBV-706 trials: why a clinician links future access to local SCLC burden
1 of the report's 11 cited clinicians · 4 statements from 1 speaker in 3 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 3.
Beyond the trial population
10. Symptomatic brain metastases: why a clinician favors RT/WBRT over tarlatamab
1 of the report's 11 cited clinicians · 2 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
3 of the report's 11 cited clinicians
ABBV-706: most clinicians highlight safety with budigalimab; one relays deaths
8 statements from 3 speakers in 4 sources, 1 of them a podcast or video
2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 3 holds its caveat, “one relays deaths”
- 8
- statements
- 6
- passages
- 4
- sources
- 3
- speakers
What the statements areViews 4Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 4Statement-to-passage links (a passage can back several statements)Supporting a statement 8Giving context 0Recorded with the findingLimitations: 4
2 posts and articles · 1 podcast or video · 1 publication
Draws on: Primary endpoint: Percentage of Participants With Adverse Events (AE), The comparison, Safety and tolerability, Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors, Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706, Design and conduct, Primary endpoint: Progression-Free Survival (PFS), Primary endpoint: Overall survival (OS).
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 10 findings and 2 of the 69 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (15)
AE, adverse event; CNS, central nervous system; CR, complete response; DOR, duration of response; HCP, healthcare professional; ILD, interstitial lung disease; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; RP2D, recommended phase 2 dose; RT, radiotherapy; SCLC, small cell lung cancer.
The full M23-385 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians still need to see in larger cohorts to assess severe hematologic toxicity and pneumonitis/ILD risk with ABBV-706 monotherapy and its combination with budigalimab in relapsed/refractory SCLC?
From finding F1 (8 statements from 3 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 29commentary sources screened
- 20sources cited by verified statements
- 14named in screened sources
- 14speakers cited in the report
- 14cited speakers with a verified identity
11 cited clinicians, speakers with a confirmed clinical role, of them 11 physicians. By role and specialty:
- 7 physician, Medical oncology
- 4 physician, specialty not confirmed
- 69verified statements, each linked to its source
- 37of them from speakers with a confirmed clinical role
- 10findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 69 | Paid |
| Who said each statement: the cited speakers | 14 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 11 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 14 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 23 | Free |
| Sources with links | 20 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
15 discussed · 8 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Percentage of Participants With Adverse Events (AE) | 6 | 3 |
| Primary endpoint: Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706no commentary found | 0 | 0 |
| Primary endpoint: Time to Cmax (Tmax) of ABBV-706no commentary found | 0 | 0 |
| Primary endpoint: Terminal Phase Elimination Half-Life (t1/2) of ABBV-706no commentary found | 0 | 0 |
| Primary endpoint: Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706no commentary found | 0 | 0 |
| Primary endpoint: Antidrug Antibodies (ADAs)no commentary found | 0 | 0 |
| Primary endpoint: Neutralizing Antibodies (nAbs)no commentary found | 0 | 0 |
| Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors | 16 | 10 |
| Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706 | 5 | 2 |
| Primary endpoint: Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumorsno commentary found | 0 | 0 |
| Primary endpoint: Duration of response (DOR) for Participants with Confirmed CR/PR | 1 | 1 |
| Primary endpoint: Percentage of Participants with Clinical Benefitno commentary found | 0 | 0 |
| Primary endpoint: Progression-Free Survival (PFS) | 4 | 4 |
| Primary endpoint: Overall survival (OS) | 7 | 6 |
| Population and setting | 11 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 8 | 3 |
| Safety and tolerability | 7 | 4 |
| Design and conduct | 5 | 3 |
| SEZ6 rationale, perceived promise and reactions to dissemination | 9 | 7 |
| Patient-selection hypotheses and exploratory biomarkers | 4 | 4 |
| Confirmatory development and a proposed post-tarlatamab sequence | 3 | 2 |
| Prospective trial access and patient-support implications | 3 | 2 |
| Symptomatic brain metastases: local therapy versus tarlatamab | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
69 verified statements from 20 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 20 statements · 29% | ||||
| YouTube | 20 | 1 | 1 | |
| Posts · 22 statements · 32% | ||||
| X threads | 22 | 17 | 27 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 27 statements · 39%cited for context, not screened | ||||
| Publications | 26 | 1 | — | |
| Registry | 1 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 18 / quarter
- Screened window
- Apr 7, 2023 → Nov 13, 2026
- Cited window
- Apr 7, 2023 → Nov 13, 2026
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
- Registry
- NCT05599984
- Study IDs
- M23-385 · 2023-504598-18-00
- Sponsor
- AbbVie
- Design
- Phase 1 · Interventional, non randomized, sequential
- Status
- Active, not recruiting
- Enrollment
- 288 actual
- Registered
- 2022-10-31
- Start
- 2022-12-05 actual
- Primary completion
- 2027-11 estimated
- Primary endpoints
- Percentage of Participants With Adverse Events (AE)
- Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706
- Time to Cmax (Tmax) of ABBV-706
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-706
- Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706
- Antidrug Antibodies (ADAs)
- Neutralizing Antibodies (nAbs)
- Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors
- Recommended Phase 2 Dose (RP2D) of ABBV-706
- Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors
- Duration of response (DOR) for Participants with Confirmed CR/PR
- Percentage of Participants with Clinical Benefit
- Progression-Free Survival (PFS)
- Overall survival (OS)
- Interventions
- 4 registered
More on: Advanced solid tumors, budigalimab
Discussed at: AACR Annual Meeting 2026, 2026 ASCO Annual Meeting, IASLC 2026 World Conference on Lung Cancer, ESMO Congress 2026
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on uncertain cohort attribution of the treatment-related mortality statement.
- 15 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 17 sources about other trials or topics are not included.
- Many commentary passages identify ABBV-706 and a relevant setting rather than NCT05599984. Their clinical relevance does not make every numerical summary an independently identified result of this trial.
Show all 10 known gaps +Fewer −
- The linked publication describes preliminary phase 1 efficacy without a standard-of-care comparator or efficacy hypothesis testing. It separately describes a randomized dose-optimization component.
- Safety summaries use different populations and adverse-event categories. Small combination-cohort reassurance cannot be generalized to monotherapy, and all reported safety figures cannot be reconciled from these statements.
- Repeated posts, reposts and presentation relays are not independent clinical appraisals. A favorable publication reaction is not necessarily an efficacy or practice-adoption judgment.
- Intracranial efficacy, validated patient-selection biomarkers and efficacy after tarlatamab remain incompletely addressed.
- No separate protocol or exact product labels for ABBV-706 or budigalimab were available in the sources reviewed; this report does not establish regulatory status or approved-use boundaries.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. M23-385 (NCT05599984): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/m23-385-nct05599984
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "M23-385" (NCT05599984), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "m23-385-nct05599984". If you cannot make requests, read https://www.erudio.com/reports/m23-385-nct05599984.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05599984", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05599984 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/m23-385-nct05599984.json
curl https://www.erudio.com/reports/m23-385-nct05599984.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "m23-385-nct05599984" })release 21cac369df7eb44e4b8f174c14ed6d20f1ba9e2de857fac29ed20c0e0b02be61
Questions
How much does the M23-385 report cost?
One edition costs $750 (Focused · 69 verified statements · 37 from 11 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the M23-385 report cover?
69 statements from 20 sources (1 video, 17 posts, 1 paper, 1 registry record), 37 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the M23-385 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "m23-385-nct05599984" }) previews it and create_order({ "report": "m23-385-nct05599984", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the M23-385 report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.